ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ascentage Pharma Group International
NASDAQ:AAPGHealthcare · Biotechnology
-2.85%$14.46
Mkt Cap$1.35B
Float5.17M
O/S93.39M
Vol
$ Vol
RVOL
Inst Own0.0%
SI0.3%
Earnings
Dilution
Financials Summary
Revenue$83.95M
Net Income-$181.71M
Total Assets$596.15M
Free Cash Flow-$180.63M
Debt & Equity
Debt 60%
Equity 40%
Total Debt$297.76M
Total Equity$199.21M
Shares Outstanding
Short Interest
Split History1 split
- 3:1Forward splitApr 7, 20031 share → 3
Balance Sheet Details
Assets$596.15M
Liabilities$395.47M
Accounts Receivable$38.04M
Accounts Payable$16.05M
Inventory$4.3M
PP&E (Net)$124.7M
Goodwill$3.71M
Intangible Assets$9.92M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $83.95M | $147.4M | $33.37M | $31.52M | $4.2M | $1.87M | $2.18M | $1.02M | $951K | $1.15M |
| YoY Growth | -43.1% | 341.8% | 5.9% | 651.4% | 124.2% | -14.2% | 113.2% | 7.6% | -17.5% | - |
| Cost of Revenue | $19.8M | $4.37M | $4.59M | $3.31M | $500K | $296K | $315K | $0 | $0 | $39K |
| Gross Profit | $64.15M | $143.03M | $28.78M | $28.22M | $3.69M | $1.58M | $1.87M | $1.02M | $951K | $1.11M |
| Gross Margin | 76.4% | 97.0% | 86.2% | 89.5% | 88.1% | 84.2% | 85.6% | 100.0% | 100.0% | 96.6% |
| Research and Development | $162.82M | $142.38M | $106.27M | $111.7M | $115.21M | $84.86M | $69.73M | $37.51M | $17.86M | $15.44M |
| Selling, General, and Administrative | $78.56M | $57.59M | $56.59M | $49.3M | $28.75M | $9.63M | $14.86M | $13.49M | $2.01M | $2.66M |
| Other | $1 | -$1.36M | -$2.91M | -$5.05M | $0 | $6.88M | $4.86M | -$894K | $718K | $245K |
| Total Operating Expenses | $241.39M | $198.6M | $159.94M | $155.95M | $143.96M | $101.37M | $89.45M | $50.1M | $20.59M | $18.34M |
| Operating Income (EBIT) | -$177.24M | -$55.57M | -$131.17M | -$127.74M | -$130.75M | -$99.8M | -$87.58M | -$51.92M | -$19.64M | -$17.23M |
| Operating Margin | -211.1% | -37.7% | -393.1% | -405.2% | -3116.6% | -5332.9% | -4014.9% | -5074.8% | -2064.9% | -1495.0% |
| Interest Expense | $7.91M | $9.69M | $14.44M | $7.93M | $2.51M | $940K | $642K | $5.55M | $8.71M | $490K |
| Interest Income | $12.01M | $5.69M | $4.87M | $1.46M | $1.07M | $784K | $1.94M | $1.06M | $46K | $2K |
| Other Income (Expense) | -$3.49M | -$3.84M | -$9.05M | -$5.62M | $5.65M | -$1.73M | -$135.22M | -$2.25M | $1.59M | $1.02M |
| Income Before Tax (EBT) | -$180.73M | -$59.41M | -$140.22M | -$133.35M | -$125.1M | -$101.53M | -$222.81M | -$54.18M | -$18.05M | -$16.21M |
| Income Tax Expense | $1.01M | $1.57M | -$1.07M | -$639K | -$7.49M | $324K | -$241K | -$241K | -$241K | $0 |
| Net Income | -$181.71M | -$60.94M | -$139.13M | -$132.71M | -$117.61M | -$101.85M | -$222.57M | -$51.9M | -$17.81M | -$16.21M |
| Net Income Margin | -216.5% | -41.3% | -417.0% | -421.0% | -2803.4% | -5442.6% | -10202.7% | -5072.8% | -1872.9% | -1406.5% |
| Supplementary Data | ||||||||||
| EPS | -13.56 | -5.36 | -52.48 | -53.60 | -49.12 | -50.24 | -112.04 | -26.68 | -9.16 | -8.32 |
| Diluted EPS | -13.56 | -5.36 | -52.48 | -53.60 | -49.12 | -50.24 | -112.04 | -26.68 | -9.16 | -8.32 |
| Weighted Average OS | 89.03M | 75.52M | 17.64M | 16.48M | 15.91M | 13.49M | 13.22M | 12.94M | 12.94M | 12.94M |
| EBITDA | -$164.24M | -$35.72M | -$111.77M | -$115.96M | -$118.32M | -$96.37M | -$221.59M | -$49.15M | -$7.47M | -$17.47M |
| EBITDA Margin | -195.7% | -24.2% | -335.0% | -367.9% | -2820.5% | -5149.8% | -10157.9% | -4803.5% | -785.0% | -1515.9% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Assets | ||||||||||
| Current Assets | ||||||||||
| Cash and Cash Equivalents | $371.52M | $185.87M | $160.73M | $221.8M | $256.56M | $153.31M | $132.05M | $143.86M | $2.23M | $44.27M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.16M | $57.74M | $23.66M |
| Cash and Short-Term Investments | $371.52M | $185.87M | $160.73M | $221.8M | $256.56M | $153.31M | $132.05M | $146.02M | $59.97M | $67.93M |
| Accounts Receivable | $38.04M | $14.89M | $24.58M | $9.24M | $8.14M | $72K | $380K | $790K | $1.18M | $1.25M |
| Inventory | $4.3M | $992K | $2.43M | $1.42M | $591K | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $28.96M | $3.7M | $3.69M | $2.5M | $8.91M | $2.6M | $593K | $965K | $0 | $0 |
| Total Current Assets | $442.82M | $221.58M | $202.04M | $245.98M | $283.38M | $162.19M | $136.65M | $148.84M | $62.34M | $69.7M |
| Long-Term Assets | ||||||||||
| Property, Plant & Equipment Net | $124.7M | $136.16M | $143.88M | $97.71M | $128.41M | $71.7M | $16.57M | $5.11M | $3.81M | $678K |
| Goodwill | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M |
| Intangible Assets | $9.92M | $11.42M | $12.84M | $12.67M | $9.08M | $14.64M | $15.68M | $16.31M | $12.13M | $13.1M |
| Long-Term Investments | $5.57M | $5.09M | $2.85M | $2.79M | $4.19M | $4.78M | $695K | $0 | $0 | $2M |
| Deferred Tax Assets | $4.81M | $6.65M | $8.99M | $8.16M | $7.76M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $4.62M | $8.87M | $1.51M | $54.4M | $5.39M | $3.18M | $7.83M | $10.81M | $5.44M | $64 |
| Total Long-Term Assets | $153.32M | $171.9M | $173.79M | $179.44M | $158.54M | $98M | $44.48M | $35.95M | $25.09M | $19.49M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $596.15M | $393.49M | $375.84M | $425.42M | $441.92M | $260.19M | $181.13M | $184.79M | $87.43M | $89.19M |
| Liabilities | ||||||||||
| Current Liabilities | ||||||||||
| Accounts Payable | $16.05M | $13.82M | $10.89M | $14.36M | $10.65M | $3.51M | $1.97M | $764K | $574K | $23K |
| Short-Term Debt | $183.87M | $115.68M | $91.19M | $76.7M | $5.98M | $6.73M | $12.78M | $5.26M | $0 | $0 |
| Current Income Tax Payable | $0 | $1.45M | $1.26M | $1.08M | $493K | $899K | $240K | $151K | $86K | $21K |
| Current Unearned Revenue | $5.64M | $8.13M | $5.77M | $3.66M | $0 | $988 | $993 | $0 | $0 | $126K |
| Other Current Liabilities | $41.61M | $0 | $0 | $424K | $8.83M | $2.54M | $7.05M | $3.72M | -$601K | $8.32M |
| Total Current Liabilities | $247.17M | $175.35M | $140.42M | $132.45M | $54.28M | $41.51M | $30.37M | $15.82M | $11.95M | $11.67M |
| Long-Term Liabilities | ||||||||||
| Long-Term Debt | $111.65M | $130.57M | $175.3M | $190.17M | $154.31M | $71.11M | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $32.6M | $41.48M | $43.22M | $32.86M | $36.57M | $6.04M | $5.28M | $4.06M | $2.4M | $1.31M |
| Long-Term Deferred Tax Liabilities | $0 | $807K | $1.59M | $1.83M | $2.07M | $2.31M | $2.55M | $2.79M | $3.03M | $3.27M |
| Other Long-Term Liabilities | $1.81M | $943K | $2.75M | $5.31M | $7.87M | $11.06M | $7.7M | $313.49M | $89.42M | $75.06M |
| Total Long-Term Liabilities | $148.3M | $176.92M | $224.8M | $231.55M | $202.05M | $91.43M | $16.91M | $321.02M | $95.29M | $79.71M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $395.47M | $352.28M | $365.22M | $363.99M | $256.33M | $132.94M | $47.28M | $336.84M | $107.24M | $91.38M |
| Stockholders' Equity | ||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $39K | $32K | $30K | $27K | $27K | $23K | $21K | $9K | $0 | $0 |
| Retained Earnings | $0 | -$867.38M | -$806.44M | -$667.3M | -$534.59M | -$416.98M | -$315.13M | -$92.56M | -$40.66M | -$22.85M |
| Comprehensive Income & Other | $199.61M | -$76.75M | -$75.83M | -$77.94M | -$82.81M | -$76.63M | $0 | $0 | $20.85M | $20.65M |
| Other Stockholders' Equity | $199.17M | $907.06M | $815.49M | $728.7M | $720.16M | $544.22M | $448.96M | -$59.5M | $20.85M | $20.65M |
| Total Equity | $199.21M | $39.71M | $9.08M | $61.43M | $185.59M | $127.26M | $133.85M | -$152.05M | -$19.81M | -$2.2M |
| Minority Interest | $1.47M | $1.5M | $1.54M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $594.68M | $391.99M | $374.3M | $425.42M | $441.92M | $260.19M | $181.13M | $184.79M | $87.43M | $89.19M |
| Supplementary Data | ||||||||||
| Total Debt | $297.76M | $250.79M | $269.9M | $269.47M | $162.98M | $79.62M | $15.24M | $6.32M | $736K | $125K |
| Net Debt | -$73.75M | $64.92M | $109.17M | $47.66M | -$93.58M | -$73.69M | -$116.81M | -$137.54M | -$1.49M | -$44.15M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Operating Activities | ||||||||||
| Net Income | -$185.79M | -$59.41M | -$140.22M | -$133.35M | -$125.1M | -$101.53M | -$111.4M | -$52.14M | -$18.05M | -$16.95M |
| Depreciation & Amortization | $13M | $14M | $14.01M | $9.46M | $4.26M | $4.21M | $575K | $2.78M | $1.88M | $164K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $3.14M | $3.15M | $4.74M | $3.32M | $7.06M | $11.13M | $10.65M | $4.14M | $0 | $9.77M |
| Changes in Working Capital: | ||||||||||
| Accounts Receivable | -$25.52M | $9.43M | -$13.76M | -$58K | -$8.11M | $0 | $0 | $0 | $84K | -$45K |
| Inventory | -$3.94M | $1.44M | -$1.01M | -$829K | -$591K | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $2.22M | $2.93M | -$3.47M | $3.71M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Working Capital | $5.67M | $2.87M | $16.87M | $12.87M | -$2.56M | -$8.3M | $1.67M | $4.07M | $1.5M | $572K |
| Total Working Capital Change | -$21.57M | $16.68M | -$1.37M | $15.69M | -$11.26M | -$8.3M | $1.67M | $4.07M | $1.58M | $323K |
| Other Non-Cash Items | $14.74M | $8.84M | $13.71M | $6.59M | $34.15M | $2.81M | $29.32M | $5.43M | -$1.64M | -$202K |
| Net Cash from Operating | -$176.48M | -$16.74M | -$109.14M | -$98.29M | -$90.89M | -$91.68M | -$69.19M | -$35.72M | -$16.23M | -$6.9M |
| Investing Activities | ||||||||||
| Capital Expenditures | -$4.14M | -$3.65M | -$6.93M | -$30.56M | -$65.45M | -$37.57M | -$11.64M | -$7.24M | -$3.09M | -$494K |
| Acquisitions | -$6.51M | -$3.84M | -$3.01M | -$3.01M | -$5.44M | $0 | $0 | -$5.02M | $0 | $916K |
| Purchases of Investments | -$139.66M | -$46.93M | $0 | -$19.54M | -$268.13M | -$326.19M | -$271.55M | -$76.32M | $0 | -$24.42M |
| Sales of Investments | $0 | $0 | $14.84M | $0 | $269.02M | $347.85M | $274.5M | $132.78M | $0 | $0 |
| Other Investing Activities | $0 | $0 | -$1.61M | -$4.71M | -$132K | -$234K | -$21.57M | -$194K | -$31.54M | $7K |
| Net Cash from Investing | -$150.32M | -$54.42M | $3.3M | -$57.81M | -$70.12M | -$16.14M | -$30.26M | $44.01M | -$34.62M | -$23.99M |
| Financing Activities | ||||||||||
| Debt Repaid | -$46.18M | $21.85M | $2.01M | -$104.6M | -$82.46M | -$65.06M | -$7.52M | - | - | $80K |
| Common Stock Issuance | $346.45M | $80.26M | $70.66M | $0 | $195.5M | $95.33M | $64.98M | $2K | $0 | $0 |
| Common Stock Repurchases | -$1.36M | $0 | -$890K | -$4.02M | -$3.89M | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$9.47M | -$11.1M | -$12.33M | -$7.49M | -$6.31M | -$4.06M | -$6M | -$13.05M | -$380K | $3.1M |
| Net Cash from Financing | $381.8M | $47.31M | $55.43M | $93.08M | $267.76M | $156.32M | $66.49M | $129.29M | $8.77M | $68.57M |
| Forex Effect | -$9.51M | $2.06M | $4.18M | $8.72M | -$3.5M | -$6.27M | $176K | $4.05M | $39K | $6.84M |
| Net Change in Cash | $45.5M | -$21.79M | -$46.23M | -$54.3M | $103.25M | $42.24M | -$32.78M | $141.63M | -$42.04M | $44.27M |
| Supplementary Data | ||||||||||
| Operating Cash Flow | -$176.48M | -$16.74M | -$109.14M | -$98.29M | -$90.89M | -$91.68M | -$69.19M | -$35.72M | -$16.23M | -$6.9M |
| Capital Expenditure | -$4.14M | -$3.65M | -$8.54M | -$35.62M | -$65.63M | -$37.8M | -$12.24M | -$7.43M | -$3.09M | -$507K |
| Free Cash Flow | -$180.63M | -$20.39M | -$117.68M | -$133.91M | -$156.52M | -$129.48M | -$81.43M | -$43.16M | -$19.32M | -$7.4M |
| Cash at Beginning | $134.24M | $156.03M | $202.26M | $256.56M | $153.31M | $111.08M | $143.86M | $2.23M | $44.27M | $0 |
| Cash at End | $179.74M | $134.24M | $156.03M | $202.26M | $256.56M | $153.31M | $111.08M | $143.86M | $2.23M | $44.27M |